8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 28, 2026·SEC
Rocket Pharmaceuticals, Inc.(RCKT)Earnings, Financials & Key Ratios
RCKT•NASDAQ
$4.07
Price updated Jul 7, 2026
AboutRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.Show more
- Revenue$0
- EBITDA-$217M+17.6%
- Net Income-$223M+13.8%
- EPS (Diluted)-2.01+26.4%
- ROE-60.27%-11.3%
RCKT Price & Volume
Rocket Pharmaceuticals, Inc. (RCKT) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Capital Runway Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Capital runway and dilution
Key Thesis Takeaways
- Rocket Pharmaceuticals remains in a high-risk, pre-revenue phase, with its valuation heavily dependent on the successful clinical execution of its gene therapy pipeline.
- The company faces significant financial pressure as quarterly operating losses consistently range between $44 million and $73.7 million, necessitating potential future dilution to fund ongoing R&D.
- Investors should monitor the company's ability to reach commercialization before its current cash reserves, which declined to $49.6 million in 2026Q1, are fully exhausted.
Verdict Logic
the rapid depletion of cash reserves from $77.6 million in 2025Q4 to $49.6 million in 2026Q1 suggests an imminent need for dilutive financing to sustain clinical operations.
RCKT Growth Metrics
Rocket Pharmaceuticals, Inc. (RCKT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM18.85%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM28.9%
Return on Capital
10 Years-39.94%
5 Years-48.13%
3 Years-54.28%
Last Year-58.05%
RCKT Recent Earnings
Rocket Pharmaceuticals, Inc. (RCKT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.42-2.4%
$0.41
Rev
—
$4M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.38+9.5%
$0.42
Rev
—
$277,778
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.45+6.3%
$0.48
Rev
—
$312,500
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.59-3.5%
$0.57
Rev
—
$4M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.42vs $0.41-2.4% | —vs $4M |
| Q1 2026 | Feb 26, 2026 | $0.38vs $0.42+9.5% | —vs $277,778 |
| Q4 2025 | Nov 6, 2025 | $0.45vs $0.48+6.3% | —vs $312,500 |
| Q3 2025 | Aug 7, 2025 | $0.59vs $0.57-3.5% | —vs $4M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Rocket Pharmaceuticals, Inc. (RCKT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.07 | $444.42M | -2.02 | — | — | -60.27% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $3.75 | $367.15M | -2.08 | 25.39% | -281.59% | -677.39% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $0.07 | $30.66M | -0.17 | -31.57% | -356.89% | — | — |
Compare RCKT vs Peers
Rocket Pharmaceuticals, Inc. (RCKT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RCKT SEC Filings & Documents
Rocket Pharmaceuticals, Inc. (RCKT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when RCKT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RCKT Frequently Asked Questions
Rocket Pharmaceuticals, Inc. (RCKT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is RCKT profitable?
Rocket Pharmaceuticals, Inc. (RCKT) reported a net loss of $209.4M for fiscal year 2025.
Dividend & Returns
What is RCKT's return on equity?
Rocket Pharmaceuticals, Inc. (RCKT) has a return on equity (ROE) of -60.3%. Negative ROE indicates the company is unprofitable.
What is Rocket Pharmaceuticals, Inc.'s free cash flow?
Rocket Pharmaceuticals, Inc. (RCKT) had negative free cash flow of $179.8M in fiscal year 2025, likely due to heavy capital investments.